CODX - Co-Diagnostics, Inc.
0.3199
0.009 2.907%
Share volume: 195,841
Last Updated: 04-07-2025
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies:
-0.01%
PREVIOUS CLOSE
CHG
CHG%
$0.31
0.01
0.03%
Fundamental analysis
24%
Profitability
0%
Dept financing
5%
Liquidity
75%
Performance
40%
Company vs Stock growth
vs
641.141 K
149.325 K
-491.816 K
-76.71%
1.180
0.392
-0.789
-66.82%
Performance
5 Days
-0.96%
1 Month
-40.21%
3 Months
-58.74%
6 Months
-75.77%
1 Year
-73.78%
2 Year
-78.60%
Key data
Stock price
$0.32
DAY RANGE
$0.29 - $0.38
52 WEEK RANGE
$0.28 - $2.23
52 WEEK CHANGE
-$74.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
Company detail
CEO: Dwight H. Egan
Region: US
Website: codiagnostics.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Region: US
Website: codiagnostics.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Co-Diagnostics, Inc. develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and analysis of nucleic acid molecules. Company also provides tests that identify genetic traits in plant and animal genomes. Company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recent news
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read moreCo-Diagnostics Full Year 2024 Earnings: Misses Expectations
Co-Diagnostics ( NASDAQ:CODX ) Full Year 2024 Results Key Financial Results Net loss: US$37.6m (loss widened by 6.5...
Read more